"Differential Metabolomic Profile on End-Stage Ischemic and Non-Ischemi" by Renzo Loyaga-Rendon, Nadia Ashrafi et al.
 

Differential Metabolomic Profile on End-Stage Ischemic and Non-Ischemic Cardiomyopathy

Document Type

Conference Proceeding

Publication Date

4-2025

Publication Title

Journal of Heart and Lung Transplantation

Abstract

Purpose: Ischemic (ICMP) and non-ischemic cardiomyopathies (NICMP) can lead to end-stage heart failure (ESHF). Despite differing causes, treatment for ESHF is similar. We compared the metabolomic profiles of ESHF patients with ICMP and NICMP to identify potential metabolic differences or shared mechanisms. Methods: Blood (n=96) and myocardial tissue (n=119) samples were obtained from ESHF patients at the time of left ventricular assist device (LVAD) implantation. Metabolic analysis was conducted using the Biocrates Quant 500 XL assay which integrates targeted liquid chromatography-mass spectrometry (LC-MS) with proton nuclear magnetic resonance spectroscopy (¹H NMR). Linear modeling, metabolic pathway enrichment, metabolite functional analysis, and machine learning were used to identify alterations in biochemical pathways. Results: We measured 600 metabolites in serum and 526 metabolites in tissue. We saw significant differences between ICMP and NICMP in both blood (n=12 metabolites) and tissue (n=88 metabolites) after adjusting for multiple testing. Glycerophosphoethanolamines were upregulated in blood from ICMP patients, while both glycerophosphoethanolamines and obesity-related pathways were downregulated in tissue (Fig 1 B, E). Metabolite functional analysis identified differences in 4 of 32 metabolite groups in blood and 13 of 19 in tissue, with larger variations seen in tissue (Fig 1C,F). Conclusion: Metabolomic profiling of blood and tissue in ICMP and NICMP patients revealed distinct biochemical signatures. We identified key metabolite groups and pathways related to lipid metabolism. These findings suggest tissue-specific metabolic alterations according to ESHF etiology. This highlights potential differential biomarkers and therapeutic targets between ICMP and NICMP

Volume

44

Issue

4 Suppl

First Page

S236

Comments

International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting, April 27-30, 2025, Boston, MA

Last Page

S236

DOI

10.1016/j.healun.2025.02.482

Share

COinS